Jian-Wei Li

发表

Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule.

Keda Yu, Z. Shao, Jiong Wu, 2013, The oncologist.

Prior Local or Systemic Treatment: A Predictive Model Could Guide Clinical Decision-Making for Locoregional Recurrent Breast Cancer

Jian-wei Li, Huai-liang Wu, Guangrong Liu, 2022, Frontiers in Oncology.

Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial

Guangyu Liu, Jian-wei Li, W. Zuo, 2018, Breast Cancer Research and Treatment.

Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.

Guangyu Liu, Jiong Wu, Z. Shao, 2015, Asian Pacific journal of cancer prevention : APJCP.

Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival

Guangyu Liu, Jiong Wu, Zhen-zhou Shen, 2018, Breast Cancer Research and Treatment.

Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer

Guangyu Liu, Zhen-zhou Shen, Z. Shao, 2015, Oncotarget.

Nomograms for prediction of breast cancer in breast imaging reporting and data system (BI-RADS) ultrasound category 4 or 5 lesions: A single-center retrospective study based on radiomics features

Jian-wei Li, Sheng Chen, Zhi-liang Hong, 2022, Frontiers in Oncology.

Liquid Biopsy and Tissue Biopsy Comparison with Digital PCR and IHC/FISH for HER2 Amplification Detection in Breast Cancer Patients

Xin Hu, Guangyu Liu, Wentao Yang, 2022, Journal of Cancer.

Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial

Guangyu Liu, Bing-he Xu, D. Pang, 2018, Cancer management and research.

Intraoperative Touch Imprint Cytology in Targeted Axillary Dissection After Neoadjuvant Chemotherapy for Breast Cancer Patients with Initial Axillary Metastasis

Guangyu Liu, N. Zhang, Jian-wei Li, 2018, Annals of Surgical Oncology.

ER-Poor and HER2-Positive: A Potential Subtype of Breast Cancer to Avoid Axillary Dissection in Node Positive Patients after Neoadjuvant Chemo-Trastuzumab Therapy

Keda Yu, Z. Shao, Guangyu Liu, 2014, PloS one.

Clinical observation on the effect of Chinese medicine-"TCM formula" intervention on recurrence and metastasis of triple negative breast cancer.

Jian-wei Li, Sheng Liu, Chenping Sun, 2020, Complementary therapies in medicine.

Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer

Guangyu Liu, Z. Shao, Yifan Xie, 2021, Frontiers in Oncology.

MRI-Based Radiomic Signature as a Prognostic Biomarker for HER2-Positive Invasive Breast Cancer Treated with NAC

Shao-Feng Duan, Yajia Gu, Qin Xiao, 2020, Cancer management and research.

Widowed status predicts poor overall survival of Chinese patients with prostate cancer

Xue-feng Su, Silin Huang, Yi-Ning Li, 2020, Translational cancer research.

Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer

Guangyu Liu, Zhen-zhou Shen, Z. Shao, 2015, OncoTargets and therapy.

Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer

Guangyu Liu, Zhen-zhou Shen, Z. Shao, 2015, OncoTargets and therapy.

Subtype-Guided 18 F-FDG PET/CT in Tailoring Axillary Surgery Among Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: A Feasibility Study.

Guangyu Liu, Z. Shao, N. Zhang, 2020, The Oncologist.

Subtype-Guided 18F-FDG PET/CT in Tailoring Axillary Surgery Among Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: A Feasibility Study.

Guangyu Liu, Z. Shao, N. Zhang, 2019, The oncologist.

Value of Machine Learning with Multiphases CE-MRI Radiomics for Early Prediction of Pathological Complete Response to Neoadjuvant Therapy in HER2-Positive Invasive Breast Cancer

Yajia Gu, Qin Xiao, Zhe Wang, 2021, Cancer management and research.

The volumetric-tumour histogram-based analysis of intravoxel incoherent motion and non-Gaussian diffusion MRI: association with prognostic factors in HER2-positive breast cancer

Weijun Peng, Wentao Yang, Chao You, 2019, Journal of Translational Medicine.

Re-Evaluate the Value of Frozen Sections in Diagnoses of Breast Malignancies that Failed to be Diagnosed by Core Needle Biopsy: A Chinese Retrospective Analysis of Clinical Practice

Guangyu Liu, Qiuxia Cui, Y. Gong, 2021 .

Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer

Weijun Peng, Guangyu Liu, Chao You, 2018, Acta radiologica.

Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study

Kairui Jin, Junjie Li, Z. Shao, 2023, International journal of surgery.

accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with er-positive breast cancer

Z. Shao, Q. Hong, M. Mo, 2015 .

Indispensability of chemotherapy in estrogen receptor-negative early breast cancer in elderly women with diabetes mellitus.

Guangyu Liu, Z. Shao, Jingyi Cheng, 2015, Diabetes technology & therapeutics.